

Topical Collection

Research on Monoclonal Antibodies and Antibody Engineering

Message from the Collection Editor

Our Special Issue, “Passive Immune Prophylaxis and Therapy”, focuses on passive immune prophylaxis and therapy using monoclonal antibodies (mAbs) for a variety of diseases. As you well know, current mAb-based products have attracted much attention for being one of the most effective molecular target drugs, and have also financially succeeded in developed markets. However, several obstacles hinder the widespread use of antibody drugs, such as a high production cost, the necessity of weekly or biweekly infusions due to short half-life (approximately 20 days), quality control, laborious development of the effective mAbs, shedding the target, antigenic variations and unwanted side effects. To address the above problems, and to share your interesting knowledge in the field of passive immunization, we are inviting you to submit original research or review to this Special Issue on one of the following topics: (i) The methods of administration; (ii) Antibody engineering; (iii) How to develop the effective mAbs; (iv) Prophylactic or therapeutic mAb against virus. We are looking forward to your interesting manuscript.

Collection Editor

Dr. Tatsuya Yamazaki

Department of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi 480-1195, Japan



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/58213

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).